标题
Advanced Prostate Cancer Consensus Conference 2017
作者
关键词
Metastasiertes Prostatakarzinom, Systemische Therapie, Bestrahlung, Oligometastasierung, Bildgebung, Metastatic prostate cancer, Systemic therapy, Radiotherapy, Oligometastasis, Imaging
出版物
UROLOGE
Volume 57, Issue 7, Pages 813-820
出版商
Springer Nature
发表日期
2018-05-28
DOI
10.1007/s00120-018-0680-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial
- (2018) Pernelle Lavaud et al. EUROPEAN UROLOGY
- Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
- (2018) Silke Gillessen et al. EUROPEAN UROLOGY
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy
- (2016) Nicola Fossati et al. EUROPEAN UROLOGY
- Sensitivity, Specificity, and Predictors of Positive 68 Ga–Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis
- (2016) Marlon Perera et al. EUROPEAN UROLOGY
- Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
- (2016) Nicholas D James et al. LANCET
- Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
- (2015) Francesca Maines et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score
- (2015) Frederik A. Verburg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence
- (2015) A. Karl et al. WORLD JOURNAL OF UROLOGY
- Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer
- (2014) Firas Abdollah et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
- (2011) Stephane Oudard Future Oncology
- Percentage of positive biopsies predicts lymph node involvement in men with low-risk prostate cancer undergoing radical prostatectomy and extended pelvic lymphadenectomy
- (2010) Axel Heidenreich et al. BJU INTERNATIONAL
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started